Tikcro Technologies (TIKRF) 0.3710 $TIKRF
Tikcro Technologies Reports First Quarter 2016 Results
PR Newswire - Wed Jun 01, 12:43PM CDT
Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported financial results for the first quarter ended March 31, 2016.
Tikcro Technologies Reports Fourth Quarter and Year End 2015 Results
PR Newswire - Thu Mar 31, 9:01AM CDT
Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported financial results for the fourth quarter and the year ended December 31, 2015.
OTC Markets Group Welcomes Tikcro Technologies to OTCQX
PR Newswire - Tue Dec 29, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Tikcro Technologies Ltd. (OTCQX: TIKRF), an Israel-based developer of second generation antibodies binding to cancer-immune modulators, currently in pre-clinical stage, has qualified to trade on the OTCQX® Best Market.
Tikcro Adds New Cancer Immune Modulators Targets
PR Newswire - Tue Dec 15, 3:05PM CST
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it has extended an ongoing research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel, for additional targets for cancer immune modulators generated from a certain lab at the Weizmann Institute of Science.
Tikcro Technologies Announces 2015 Annual General Meeting
PR Newswire - Tue Nov 24, 7:30AM CST
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 29, 2015 at 11:00 a.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Technologies Launches New Website
PR Newswire - Mon Oct 26, 10:37AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced the launch of a new corporate website. The website features information on the Company's approach of using a novel 3D antigen design methodology to generate antibodies for the treatment of certain cancer indications by addressing immune modulators. Specifically, it describes the Company's product pipeline of antibodies for the blocking of CTLA4 and PD1 interactions with its respective ligands. The website also has a comprehensive investor section with up to date financial information and a corporate presentation. The new website is located at www.tikcro.com.
Tikcro Technologies Reports Second Quarter 2015 Results
PR Newswire - Tue Jul 14, 10:31AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results for the second quarter ended June 30, 2015.
Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan
PR Newswire - Mon Jun 15, 7:30AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints.
Tikcro Technologies Announces Approval to Continue Trading on OTCQB
PR Newswire - Tue May 05, 8:42AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that the Company was approved to continue trading on OTCQB Marketplace, the market for developmental stage companies.
Tikcro Technologies Announces Shareholders' Meeting
PR Newswire - Wed Feb 18, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that an Extraordinary General Meeting of Shareholders will be held on March 25, 2015 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Signs Research and License Agreement Regarding Cancer Immune Checkpoint Antibodies
PR Newswire - Tue Dec 30, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel. This agreement is for the development of new antibodies originating from specified research at the Weizmann Institute of Science addressing identified targets of cancer immune checkpoints.
Tikcro Technologies Reports Third Quarter 2014 Results
PR Newswire - Thu Nov 13, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the third quarter ended September 30, 2014.
Tikcro Technologies Reports First Quarter 2016 Results
PR Newswire - Wed Jun 01, 12:43PM CDT
Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported financial results for the first quarter ended March 31, 2016.
Tikcro Technologies Reports Fourth Quarter and Year End 2015 Results
PR Newswire - Thu Mar 31, 9:01AM CDT
Tikcro Technologies Ltd. (OTCQX: TIKRF) today reported financial results for the fourth quarter and the year ended December 31, 2015.
OTC Markets Group Welcomes Tikcro Technologies to OTCQX
PR Newswire - Tue Dec 29, 6:00AM CST
OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial markets, today announced Tikcro Technologies Ltd. (OTCQX: TIKRF), an Israel-based developer of second generation antibodies binding to cancer-immune modulators, currently in pre-clinical stage, has qualified to trade on the OTCQX® Best Market.
Tikcro Adds New Cancer Immune Modulators Targets
PR Newswire - Tue Dec 15, 3:05PM CST
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it has extended an ongoing research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel, for additional targets for cancer immune modulators generated from a certain lab at the Weizmann Institute of Science.
Tikcro Technologies Announces 2015 Annual General Meeting
PR Newswire - Tue Nov 24, 7:30AM CST
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders will be held on December 29, 2015 at 11:00 a.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Technologies Launches New Website
PR Newswire - Mon Oct 26, 10:37AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced the launch of a new corporate website. The website features information on the Company's approach of using a novel 3D antigen design methodology to generate antibodies for the treatment of certain cancer indications by addressing immune modulators. Specifically, it describes the Company's product pipeline of antibodies for the blocking of CTLA4 and PD1 interactions with its respective ligands. The website also has a comprehensive investor section with up to date financial information and a corporate presentation. The new website is located at www.tikcro.com.
Tikcro Technologies Reports Second Quarter 2015 Results
PR Newswire - Tue Jul 14, 10:31AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today reported results for the second quarter ended June 30, 2015.
Tikcro to Proceed with CTLA4 and PD1 Antibody Generation Plan
PR Newswire - Mon Jun 15, 7:30AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that it will proceed with a pre-clinical plan for the generation and verification of new antibodies targeting the modulation of CTLA4 and PD1 cancer checkpoints.
Tikcro Technologies Announces Approval to Continue Trading on OTCQB
PR Newswire - Tue May 05, 8:42AM CDT
Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that the Company was approved to continue trading on OTCQB Marketplace, the market for developmental stage companies.
Tikcro Technologies Announces Shareholders' Meeting
PR Newswire - Wed Feb 18, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that an Extraordinary General Meeting of Shareholders will be held on March 25, 2015 at 12:00 p.m. Israel time, at the law offices of Goldfarb Seligman & Co., Electra Tower, 98 Yigal Allon Street, 36th Floor, Tel Aviv, Israel.
Tikcro Signs Research and License Agreement Regarding Cancer Immune Checkpoint Antibodies
PR Newswire - Tue Dec 30, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today announced that it has entered into a research and license agreement with Yeda Research and Development Company Ltd., the technology transfer arm of the Weizmann Institute of Science in Israel. This agreement is for the development of new antibodies originating from specified research at the Weizmann Institute of Science addressing identified targets of cancer immune checkpoints.
Tikcro Technologies Reports Third Quarter 2014 Results
PR Newswire - Thu Nov 13, 8:00AM CST
Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the third quarter ended September 30, 2014.
